Dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders


Zafgen (NASDAQ: ZFGN) is a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by type 2 diabetes, rare diseases and other metabolic diseases. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of metabolic diseases through the MetAP2 pathway. The Company has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity, and in patients affected by type 2 diabetes. Zafgen's lead product candidate is ZGN-1061, a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor that was advanced into development due to its unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. The Company completed its first Phase 1 clinical trial of ZGN-1061, and has advanced ZGN-1061 to Phase 2 clinical testing in patients with type 2 diabetes who are obese and are failing to respond adequately to current therapies. Zafgen holds exclusive worldwide rights for the development and commercialization of ZGN-1061. The Company aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by type 2 diabetes, rare diseases and other metabolic diseases.


Year Invested: 2007
Location: Cambridge, Mass.
Visit: www.zafgen.com

Recent News

November 7, 2018
Zafgen Reports Third Quarter 2018 Operating and Financial Results

November 6, 2018
Zafgen to Present at the Stifel 2018 Healthcare Conference

November 1, 2018
Zafgen To Host Conference Call To Discuss Third Quarter 2018 Financial Results

Read More News

Associated Team Members

Kevin Starr
Partner